2026-04-29T17:33:32Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/159132025-04-22T11:45:06Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19617

00925njm 22002777a 4500 dc Valverde, Alejandro author Gordón Pidal, José M author Montero-Calle, Ana Maria author Arévalo, Beatriz author Serafín, Verónica author Calero, Miguel author Moreno‐Guzmán, María author López, Miguel Ángel author Escarpa, Alberto author Yáñez‐Sedeño, Paloma author Barderas Manchado, Rodrigo author Campuzano, Susana author Pingarrón, José M author 2022-02 Alzheimer’s disease (AD), the most common neurodegenerative disorder, demands new cost-effective and easy-to-use strategies for its reliable detection, mainly in the preclinical stages. Here, we report the first immunoplatform for the electrochemical multidetermination of four candidate protein biomarkers in blood, neurofilament light chain (NfL), Tau, phosphorylated Tau (p-Tau) and TAR DNA-Binding Protein 43 (TDP-43). It involves implementation of sandwich-type immunoassays and enzy matic labelling with horseradish peroxidase (HRP) on the surface of magnetic microbeads (MBs). Amperometric detection is performed after depositing the magnetic immunoconjugates on disposable quadruple transduction platforms by monitoring the enzymatic reduction of H2O2 mediated by hydroquinone (HQ). The immunoplatform achieved LOD values smaller than the content of target biomarkers in plasma of healthy subjects, with RSD values<5%, and lower cost and shorter assay time (60–90 min) than other available methodologies and was applied to the analysis of plasma from healthy controls and AD patients. ChemElectroChem. 2022, 9:e202200055. 10.1002/celc.202200055 2196-0216 2196-0216 ChemElectroChem http://hdl.handle.net/20.500.12105/15913 Alzheimer’s disease Candidate biomarkers Electrochemical multiplexing immunoplatform Magnetic microbeads Plasma Paving the Way for Reliable Alzheimer's Disease Blood Diagnosis by Quadruple Electrochemical Immunosensing